首页 › 基金 › BAKER BROS. ADVISORS LP › TRDA
BAKER BROS. ADVISORS LP 对 TRDA 的持仓历史
ENTRADA THERAPEUTICS INC · 医疗保健
BAKER BROS. ADVISORS LP 在 Q2 2026 的 13F 申报中披露持有 TRDA(ENTRADA THERAPEUTICS INC)5,072,730 股,市值约 US$37.3M,约占其申报组合的 0.20%,在其申报持仓中市值排名第 42 位。 BAKER BROS. ADVISORS LP 最近 12 个申报季度中有 12 个季度披露了 TRDA 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
BAKER BROS. ADVISORS LP 对 TRDA 的持仓演变
BAKER BROS. ADVISORS LP 于 Q3 2023 首次披露 TRDA 持仓:4,865,819 股(约 US$76.9M)。 该持仓在 Q4 2024 达到峰值 4,865,819 股,市值约 US$84.1M。 在 12 次申报中,BAKER BROS. ADVISORS LP 1 次增持、0 次减持、10 次保持不变。 最近一期申报(Q2 2026)显示持股 5,072,730 股、市值约 US$37.3M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 4.87M | $76.88M | 新进 |
| Q4 2023 | 4.87M | $73.43M | 持有 |
| Q1 2024 | 4.87M | $68.95M | 持有 |
| Q2 2024 | 4.87M | $69.34M | 持有 |
| Q3 2024 | 4.87M | $77.76M | 持有 |
| Q4 2024 | 4.87M | $84.13M | 持有 |
| Q1 2025 | 4.87M | $43.99M | 持有 |
| Q2 2025 | 4.87M | $32.70M | 持有 |
| Q3 2025 | 4.87M | $28.22M | 持有 |
| Q4 2025 | 5.07M | $52.15M | 增持 |
| Q1 2026 | 5.07M | $64.02M | 持有 |
| Q2 2026 | 5.07M | $37.34M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TRDA 与 13F 数据
TRDA(ENTRADA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 36 只申报持有 TRDA,申报仓位最大的包括:5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$12.8M), MPM BioImpact LLC (US$9.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TRDA 的基金
- 5AM Venture Management, LLC 4.06M 股 · $29.85M · Q2 2026
- Merck & Co., Inc. 1.74M 股 · $12.80M · Q2 2026
- MPM BioImpact LLC 1.25M 股 · $9.22M · Q2 2026
- TCG Crossover Management, LLC 1.06M 股 · $7.80M · Q2 2026
- StepStone Group LP 761.28K 股 · $5.60M · Q2 2026
- Lynx1 Capital Management LP 178.61K 股 · $1.31M · Q2 2026
更多关于 BAKER BROS. ADVISORS LP
常见问题
How long has BAKER BROS. ADVISORS LP held TRDA?
BAKER BROS. ADVISORS LP has disclosed TRDA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in TRDA?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 5.07M shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $37.34M, representing 0.20% of its reported portfolio and ranking #42.
Has BAKER BROS. ADVISORS LP been buying or selling TRDA?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in TRDA. The position peaked in Q4 2024 at 4.87M shares.
Which other funds hold TRDA?
Other major institutional holders of TRDA include 5AM Venture Management, LLC, Merck & Co., Inc., MPM BioImpact LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.